Match Document Document Title Score
US20040258719 External preparation for treating dermatosis and pruritus due to hemodialysis  
Method for treating dermatosis and pruritus due to hemodialysis by applying to a patient suffering from said diseases due to hemodialysis the external preparation containing Aspirin as an active...
122
US20030125307 Remedies for external use for allergic skin diseases  
External preparations for allergic dermatitis containing Aspirin alone as the active ingredient, which exert an excellent therapeutic effects on allergic dermatitis with lower side effects; and a...
122
US20080009024 Methods for identifying patients with increased risk of an adverse cardiovascular event  
Methods, compositions and kits are disclosed for identifying patients with an increased risk of experiencing an adverse cardiovascular event where the patient is undergoing aspirin antiplatelet...
121
5760261 Higher fatty acid derivatives of salicylic acid and salts thereof  
The present invention also relates to a method of treating aspirin-treatable conditions comprising administering to a patient in need of such treatment a compound of Formula I ##STR1##
121
4687781 Analgesic and anti-inflammatory compositions  
Analgesic and anti-inflammatory compositions are provided which comprise a therapeutically effective amount of a hydrocinnamic acid alone, or in combination with one or more amino acids selected...
121
US20060280816 Efficient method for producing compositions enriched in total phenols  
A product made by a process which results in compositions enriched in total phenols includes purification steps not involving the addition of bisulfite ions. The enriched compositions are...
121
US20080199548 Efficient method for producing compositions enriched in total phenols  
A product made by a process which results in compositions enriched in total phenols includes purification steps not involving the addition of bisulfite ions. The enriched compositions are...
121
US20080166407 Solid oral formulations for combination therapy  
Multifunctional, single, bilayer, and trilayer coated tablets for combination therapy are formed wherein the bioactive agents responsible for the therapeutic multifunctionality are present as a...
121
7368469 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events  
Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic...
120
6071514 Methods for treating thrombotic disorders  
The present invention provides a method of treatment for patients with a variety of thrombotic disorders including, but not limited to, stroke, venous thrombosis, myocardial infarction, unstable...
120
8192768 Synergistic anti-inflammatory and antioxidant dietary supplement compositions  
Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits...
120
4559329 Dietary and pharmaceutical uses of methyl-sulfonylmethane and compositions comprising it  
Methylsulfonylmethane (CH3 SO2 CH3) administered orally is effective in ameliorating the symptoms of gastrointestinal upset, e.g., produced by the ingestion of aspirin and other pharmaceuticals,...
120
4888343 Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process  
A pharmaceutical composition for relieving symptoms of dysmenorrhea and/or premenstrual syndrome comprising a combination of aspirin or ibuprofen and a diuretic from the group pamabrom and...
119
3917828 Method of reducing the undesirable gastraintestinal effects of prostaglandin synthetase inhibitors  
There is disclosed concomitant systemic administration of prostaglandins of the PGFα-type, for example, PGF2α, and a prostaglandin synthetase inhibitor, for example, indomethacin, aspirin, or...
119
US20080242643 Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula...
119
US20040176331 Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. 1 The...
118
7169809 Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The...
118
US20070021491 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events  
Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic...
118
4704269 Effervescent antacid and analgesic compositions  
Disclosed are water soluble effervescent antacid, analgesic powder and tablet formulations which in a preferred embodiment are sodium, sucrose and aspirin free. The formulation is administered...
118
US20080242722 Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events  
The invention is directed to a method for treating a cyclooxygenase-2 mediated disease or condition in a mammalian patient at risk of a thrombotic cardiovascular event, wherein the patient is on...
118
3928588 Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors  
There is disclosed concomitant systemic administration of prostaglandins of the PGFβ-type, for example, PGF2β, and a prostaglandin synthetase inhibitor, for example, indomethacin, aspirin, or...
117
8168400 Methods and kits for detection of thromboxane A2 metabolites  
Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite...
117
US20040058019 Kit and method for migraine headache treatment  
A kit and method for treating migraine headaches comprising the preparing of an oral composition containing at least two bags of black pekoe tea brewed in approximately three ounces of boiling...
116
US20120009172 INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR  
The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in...
115
4025636 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles  
2-(Optionally substituted)phenyl-benzoxazoles having a carboxy alkyl, a tetrazolyl, or oxazolinyl group at the 5 or 6 position useful as aspirin-like non-steroidal, non-narcotic, analgesic,...
115
8206741 Pharmaceutical compositions for the coordinated delivery of NSAIDs  
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The...
113
US20180228818 PHARMACEUTICAL COMPOSITION COMPRISING ASPRIN, METFORMIN, AND SEROTONIN WITH NON-IONIC SURFACTANT  
The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In...
113
7682637 Efficient method for producing compositions enriched in total phenols  
A product made by a process which results in compositions enriched in total phenols includes purification steps not involving the addition of bisulfite ions. The enriched compositions are...
113
6734208 Compounds and therapies for the prevention of vascular and non-vascular pathologies  
The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to...
113
US20110165254 Drug Delivery Using Fine Fiber Encapsulation  
The disclosure generally relates to a method of producing a handleable wafer of medicament powder (for example, aspirin powder) by utilizing a restraining envelope of fine water-soluble fibers,...
112
US20080096927 Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events  
The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a...
112
5401730 Method for reducing platelet aggregation  
Patients having a predisposition for thrombus formation are effectively treated with compositions of acetylsalicylic acid, citric acid, thiamine and/or a zinc salt. The combination of aspirin and...
111
5759836 Osteoarthritis-associated inducable isoform of nitric oxide synthetase  
An novel isoform of inducible nitric oxide synthase (OA-NOS) has been identified in osteoarthritis-affected articular cartilage. Some properties, including molecular weight, are similar to the...
110
8043826 Device for monitoring inhibition of platelet function response  
The invention provides a method of monitoring the response of platelets to a COX1 inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX 1...
109
10130719 Compositions and methods relating to salts of specialized pro-resolving mediators  
The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their...
109
6387953 Inhibition of TNF-(α)-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
108
5238686 Sustained-release pharmaceutical preparation  
A sustained-release pharmaceutical preparation comprising an admixture of uncoated and/or single walled water soluble drug, such as aspirin, and dual walled coated drug. The dual wall structure...
108
US20120100204 TGF-Beta Stimulating Agent Compositions and Combinations  
Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided.
105
10300065 Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction  
The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the...
105
US20080118572 METHODS AND COMPOSITIONS FOR REDUCING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH THE ADMINISTRATION OF ARTIFICIAL BLOOD  
Methods and compositions are provided for reducing the risk of adverse cardiovascular (CV) events associated with the administration of artificial blood. The methods involve the administration of...
105
US20060292225 WATER SOLUBLE ANALGESIC FORMULATIONS AND METHODS FOR PRODUCTION  
A water soluble analgesic composition includes a plurality of granules. Each of the granules includes a substrate core and a coating disposed on the substrate core forming an agglomerated product,...
105
6703423 Inhibition of TNFα-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
105
6710084 Inhibition of TNFα-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
105
4643894 Maltodextrin coating  
A pharmaceutical, confectionery or food tablet coated on all its exterior surfaces with maltodextrin, which masks the characteristic taste of the tablet ingredients and does not have a slimy...
104
US20100125242 EMERGENCY DOSE MEDICATION ADMINISTRATION DEVICE  
An emergency dose medication administration device suitable for administration of an effervescent therapeutic composition, such as a soluble aspirin product that when mixed with water or other...
104
9241961 Medicinal product for treating gastrointestinal ulcers  
The present invention relates to yeast cells for use in the prevention or treatment of gastric or intestinal ulcers.
104
7011854 Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof  
Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases...
104
5206386 Controlled release N-substituted pyrrolidone esters and process for the use thereof  
N-substituted cyclic lactam esters are made from biologically active organic acids and N-haloalkyl substituted cyclic lactam, preferably N-chloromethyl pyrrolidone. Such esters provide slow...
104
5041430 Oral anticoagulant/platelet inhibitor low dose formulation  
There are disclosed combination products useful for the treatment and/or prevention of a first or recurrent myocardial infarction or a first or recurrent stroke. Said combination products comprise...
103
7132451 Inhibition of TNF-α-initiated neutrophil response  
The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically...
103


Search
« search again